1. 3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine. (September 2015) Authors: Queirolo, P.; Spagnolo, F.; Picasso, V.; Simeone, E.; Grimaldi, A.M.; Curvietto, M.; Giorello, L.; Fontana, V.; Merlo, D.F.; Ascierto, P.A.; Bruzzi, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗